July 8, 2008
NICE Recommends Against GSK’s Oral Cancer Drug
The National Institute of Health and Clinical Excellence has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the UK's National Health Service, reported the Financial Times.
According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet its threshold for clinical and cost effectiveness.
The Financial Times quoted GSK as saying: "Recent evaluations of other cancer medicines have shown that demonstrating cost effectiveness in end-stage cancers is particularly challenging. Tyverb offers hope of slowing the disease to patients with advanced breast cancer who have few treatment options left."